Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in Relapsed or Refractory NKTCL
NCT02927925Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2017
- Primary completion
- Jan 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT), sponsored by Janssen Pharmaceutical. Primary endpoint: Overall Response Rate. Started Feb 2017; status: completed.
02
Drugs
daratumumab
03
Conditions
Extranodal NK/T-cell lymphoma nasal type (ENKTCL-NT)
Beyond the preview
Go deeper on NCT02927925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02927925.